Iqbal Imran, Fleischmann Roy
Curr Rheumatol Rep. 2007 Apr;9(1):31-5. doi: 10.1007/s11926-007-0019-9.
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of disability worldwide. The incidence of OA increases with age, and as longevity increases, it will cause a significant socioeconomic burden. No disease-modifying therapy is available for OA. Recent research has highlighted the role of inflammation in the progression of OA. Interleukin-1 appears to have a significant role in disease progression. Since the interleukin-1 receptor antagonist (IL-1Ra) anakinra has been used successfully in the treatment of the inflammation and bone destruction of rheumatoid arthritis, some have suggested that it may be able to retard the disease progression of OA. This article reviews the data on the use of anakinra in OA treatment.
骨关节炎（OA）是最常见的关节炎形式，也是全球致残的主要原因之一。OA的发病率随年龄增长而增加，并且随着寿命延长，它将造成重大的社会经济负担。目前尚无针对OA的改善病情的疗法。最近的研究突出了炎症在OA进展中的作用。白细胞介素-1似乎在疾病进展中起重要作用。由于白细胞介素-1受体拮抗剂（IL-1Ra）阿那白滞素已成功用于治疗类风湿关节炎的炎症和骨质破坏，一些人认为它可能能够延缓OA的疾病进展。本文综述了关于阿那白滞素用于OA治疗的数据。
